Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg
The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg for patients with diabetes type 2, WITHOUT a very high risk of cardiovascular disease AND who are not eligible for the pre-existing reimbursement of the health insurer (in combination with metformin and/or SU), will be continued. The end date for this TBR for this group of patients has not yet been determined.
Type 2 diabetes patients WITH a very high risk on cardiovascular disease are covered by the regular reimbursement of the health insurance. Very high risk is defined as:
• established cardiovascular disease; and/or
• chronic kidney disease with
− eGFR 30-44 ml/min/1,73 m2 without albuminuria or
− eGFR 30-59 ml/min per 1.73m2 with moderately elevated albuminuria (ACR > 3 mg/mmol/l); or
− eGFR ≥ 60 ml/min per 1.73 m2 with severely elevated albuminuria (ACR > 30 mg/mmol)
Who can submit a claim
Patients or their caregivers can claim the Personal Contribution Forxiga® (dapagliflozine) 10 mg or Xigduo® (dapagliflozine & metformine HCI) 5mg online or by post. Online will be the fastest option. Pharmacists can also claim this medicine on behalf of the patient. This can only be submitted online.
For more information check out the Forxiga® (dapagliflozine) 10 mg medicine page or
check out the Xigduo® (dapagliflozine & metformine HCI) 5mg medicine page.
NL-8732 Prod 02.2022